Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 2/20 | 0.34 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.32 |
| ▸ | FYN | P06241 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | AHR | P35869 | 1/20 | 0.32 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.32 |
| ▸ | TYMS | P04818 | 2/20 | 0.31 |
| ▸ | ESR1 | P03372 | 1/20 | 0.30 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.30 |
| ▸ | GPR3 | P46089 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13615927 | 1.00 | CYP1A2 (0.34) | CYP1A2ALDH1A1THRBHPGDHSD17B10 | |
| SCHEMBL13615895 | 1.00 | CYP1A2 (0.34) | CYP1A2ALDH1A1THRBHPGDHSD17B10 | |
| SCHEMBL13615847 | 0.91 | ACHE (0.34) | ACHE | |
| SCHEMBL13615820 | 0.84 | TRIM58 (0.35) | CYP1A2ALDH1A1THRBHPGDHSD17B10 | |
| SCHEMBL13615943 | 0.77 | CYP1A2 (0.33) | CYP1A2ALDH1A1THRBHPGDHSD17B10 | |
| SCHEMBL13615760 | 0.77 | CYP1A2 (0.33) | CYP1A2ALDH1A1THRBHPGDHSD17B10 | |
| SCHEMBL12405248 | 0.75 | HPRT1 (0.56) | CYP1A2ALDH1A1HPGDHSD17B10ACHE | |
| SCHEMBL12278167 | 0.75 | HPRT1 (0.56) | CYP1A2ALDH1A1HPGDHSD17B10ACHE | |
| SCHEMBL12405291 | 0.75 | HPRT1 (0.36) | ALDH1A1HSD17B10ACHEHPRT1 | |
| SCHEMBL9804982 | 0.74 | ACHE (0.32) | ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090273278-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090273278-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | OCIAD1, OCIAD2, ORMDL3 | CYP1A2 426/4885ALDH1A1 92/4885THRB 4777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.